AU2017277005B2 - Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement - Google Patents

Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement Download PDF

Info

Publication number
AU2017277005B2
AU2017277005B2 AU2017277005A AU2017277005A AU2017277005B2 AU 2017277005 B2 AU2017277005 B2 AU 2017277005B2 AU 2017277005 A AU2017277005 A AU 2017277005A AU 2017277005 A AU2017277005 A AU 2017277005A AU 2017277005 B2 AU2017277005 B2 AU 2017277005B2
Authority
AU
Australia
Prior art keywords
day
ophioglossum
compound
treatment
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017277005A
Other languages
English (en)
Other versions
AU2017277005A1 (en
Inventor
Chun-Hsiung Chang
Yuhong DONG
Shengtang Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunregen Healthcare AG
Original Assignee
Sunregen Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunregen Healthcare AG filed Critical Sunregen Healthcare AG
Publication of AU2017277005A1 publication Critical patent/AU2017277005A1/en
Application granted granted Critical
Publication of AU2017277005B2 publication Critical patent/AU2017277005B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2017277005A 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement Active AU2017277005B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08
US62/347,103 2016-06-08
PCT/CN2017/087341 WO2017211274A1 (en) 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Publications (2)

Publication Number Publication Date
AU2017277005A1 AU2017277005A1 (en) 2019-01-17
AU2017277005B2 true AU2017277005B2 (en) 2022-12-22

Family

ID=60577583

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017277005A Active AU2017277005B2 (en) 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Country Status (12)

Country Link
US (2) US11406616B2 (enExample)
EP (1) EP3468551A4 (enExample)
JP (2) JP6872805B2 (enExample)
KR (1) KR20190017873A (enExample)
CN (2) CN110300581B (enExample)
AU (1) AU2017277005B2 (enExample)
CL (1) CL2018003537A1 (enExample)
MX (1) MX2018015188A (enExample)
NZ (1) NZ749389A (enExample)
SG (1) SG11201810580PA (enExample)
TW (1) TWI749016B (enExample)
WO (1) WO2017211274A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
JP7685134B2 (ja) * 2019-11-27 2025-05-29 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
JP2024523429A (ja) * 2021-06-18 2024-06-28 サンレーゲン ヘルスケア エージー ウイルス感染の神経学的合併症の処置と予防のための新規化合物
JP2023061448A (ja) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
JPWO2024075625A1 (enExample) * 2022-10-02 2024-04-11

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089375A (ja) * 2003-09-18 2005-04-07 Noevir Co Ltd 細胞賦活剤、美白剤、及び抗酸化剤
CN102526643A (zh) * 2012-03-22 2012-07-04 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
WO2015014497A1 (en) * 2013-08-02 2015-02-05 Schweitzer-Mauduit International, Inc. Edible product comprising reconstituted plant material
CN105381182A (zh) * 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
JPH02247125A (ja) * 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
EP1289530B1 (en) 2000-06-14 2006-10-04 PORTER, William Leslie Lipids for modulating immune response
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
EP1900364B1 (en) 2001-04-18 2013-09-25 ProMetic BioSciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
WO2004103307A2 (en) 2003-05-20 2004-12-02 Baylor Research Institute Method of use of five and fifteen carbon fatty acids
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
WO2008039855A2 (en) 2006-09-26 2008-04-03 Baylor Research Institute Nutrient sensor
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR100829729B1 (ko) * 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
AU2008318196B2 (en) 2007-11-02 2014-04-10 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
MX348036B (es) 2009-12-30 2017-05-24 Baylor Res Institute Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido.
SG182414A1 (en) * 2010-01-08 2012-08-30 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
MY173496A (en) * 2010-02-10 2020-01-29 Oryza Oil & Fat Chemical Co Ltd Age production inhibitor
US20110301238A1 (en) 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
US20110306663A1 (en) 2010-06-14 2011-12-15 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
EP2407155B1 (en) * 2010-07-15 2012-12-26 Hybrigenics S.A. Formulations of inecalcitol
CN107028926A (zh) * 2011-08-26 2017-08-11 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
BR112015013349A2 (pt) 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoína para o tratamento de deficiência de transportador de glicose 1
CA2929601A1 (en) * 2013-11-14 2015-05-21 Karin Borges Neurodegenerative disorders and methods of treatment and diagnosis thereof
CN103641713B (zh) * 2013-11-15 2015-10-21 浙江大学 甘油单酯衍生物的制备方法及应用
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CA3004996A1 (en) 2015-12-04 2017-06-08 Nestec S.A. Method for improving cognition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089375A (ja) * 2003-09-18 2005-04-07 Noevir Co Ltd 細胞賦活剤、美白剤、及び抗酸化剤
CN102526643A (zh) * 2012-03-22 2012-07-04 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
WO2015014497A1 (en) * 2013-08-02 2015-02-05 Schweitzer-Mauduit International, Inc. Edible product comprising reconstituted plant material
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
CN105381182A (zh) * 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAROYI A., et al., "Not just minor wild edible forest products: consumption of pteridophytes in sub-Saharan Africa", Journal of Ethnobiology and Ethnomedicine (2014), 10:78, pages 1-9 *
UPRETI K., et al., "Ethnomedicinal uses of Pteridophytes of Kumaun Himalaya, Uttarakhand, India", Journal of American Science (2009), 5(4), pages 167-170 *

Also Published As

Publication number Publication date
CN110300581B (zh) 2023-09-08
CL2018003537A1 (es) 2019-05-03
MX2018015188A (es) 2019-08-21
JP2021113204A (ja) 2021-08-05
EP3468551A4 (en) 2020-01-22
US11406616B2 (en) 2022-08-09
KR20190017873A (ko) 2019-02-20
NZ749389A (en) 2022-12-23
CA3026152A1 (en) 2017-12-14
CN117298092A (zh) 2023-12-29
CN110300581A (zh) 2019-10-01
TW201801720A (zh) 2018-01-16
EP3468551A1 (en) 2019-04-17
WO2017211274A1 (en) 2017-12-14
JP2019518034A (ja) 2019-06-27
AU2017277005A1 (en) 2019-01-17
US20220362197A1 (en) 2022-11-17
JP6872805B2 (ja) 2021-05-19
TWI749016B (zh) 2021-12-11
US20190255129A1 (en) 2019-08-22
SG11201810580PA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
US20220362197A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
Zhu et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study
JP2023175762A (ja) 神経変性疾患のための治療薬
CN112566641A (zh) 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物
US20140243422A1 (en) Methods of treating behavioral and psychiatric disorders
US20200323870A1 (en) Method of treating dementia
US20230146896A1 (en) Composition and method for treating alzheimer's disease
WO2020222799A1 (en) A method of treating mental, behavioral, cognitive disorders
EP3197445B1 (en) Proline or proline derivatives for the treatment of dementia
WO2023034115A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
CN103037868A (zh) 异类叶升麻苷或其药学上可接受的盐的用途
CA3026152C (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2019052629A1 (en) LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
HK40021759A (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP5417727B2 (ja) 網膜保護剤
HK40021759B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
TW202539621A (zh) 用於治療巴金森氏症的治療劑
WO2003020274A1 (en) Treatment of atopic dermatitis
Marsili et al. 31 Cerebellar Ataxia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)